113 related articles for article (PubMed ID: 14684146)
41. Recent advances in hemophilia B therapy.
Horava SD; Peppas NA
Drug Deliv Transl Res; 2017 Jun; 7(3):359-371. PubMed ID: 28243977
[TBL] [Abstract][Full Text] [Related]
42. Stabilizing interactions between D666-S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting pathway.
Monaghan M; Wakabayashi H; Griffiths AE; Fay PJ
J Thromb Haemost; 2016 May; 14(5):1021-30. PubMed ID: 26878264
[TBL] [Abstract][Full Text] [Related]
43. The Importance of Exosite Interactions for Substrate Cleavage by Human Thrombin.
Chahal G; Thorpe M; Hellman L
PLoS One; 2015; 10(6):e0129511. PubMed ID: 26110612
[TBL] [Abstract][Full Text] [Related]
44. Dimeric Organization of Blood Coagulation Factor VIII bound to Lipid Nanotubes.
Dalm D; Galaz-Montoya JG; Miller JL; Grushin K; Villalobos A; Koyfman AY; Schmid MF; Stoilova-McPhie S
Sci Rep; 2015 Jun; 5():11212. PubMed ID: 26082135
[TBL] [Abstract][Full Text] [Related]
45. Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.
Tin A; Grams ME; Maruthur NM; Astor BC; Couper D; Mosley TH; Fornage M; Parekh RS; Coresh J; Kao WH
Clin J Am Soc Nephrol; 2015 May; 10(5):784-90. PubMed ID: 25887069
[TBL] [Abstract][Full Text] [Related]
46. A new recombinant factor VIII: from genetics to clinical use.
Santagostino E
Drug Des Devel Ther; 2014; 8():2507-15. PubMed ID: 25548513
[TBL] [Abstract][Full Text] [Related]
47. Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.
Sampei Z; Igawa T; Soeda T; Funaki M; Yoshihashi K; Kitazawa T; Muto A; Kojima T; Nakamura S; Hattori K
MAbs; 2015; 7(1):120-8. PubMed ID: 25524207
[TBL] [Abstract][Full Text] [Related]
48. Lipid nanotechnologies for structural studies of membrane-associated proteins.
Stoilova-McPhie S; Grushin K; Dalm D; Miller J
Proteins; 2014 Nov; 82(11):2902-9. PubMed ID: 24957666
[TBL] [Abstract][Full Text] [Related]
49. Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.
Kosloski MP; Shetty KA; Wakabayashi H; Fay PJ; Balu-Iyer SV
AAPS J; 2014 Sep; 16(5):1038-45. PubMed ID: 24934295
[TBL] [Abstract][Full Text] [Related]
50. Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit.
Monaghan M; Wakabayashi H; Griffiths A; Wintermute J; Fay PJ
Thromb Haemost; 2014 Sep; 112(3):495-502. PubMed ID: 24899227
[TBL] [Abstract][Full Text] [Related]
51. Innovative approach for improved rFVIII concentrate.
Morfini M
Eur J Haematol; 2014 Nov; 93(5):361-8. PubMed ID: 24766411
[TBL] [Abstract][Full Text] [Related]
52. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.
Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
J Pharm Sci; 2015 Feb; 104(2):388-95. PubMed ID: 24700333
[TBL] [Abstract][Full Text] [Related]
53. Cofactor activity in factor VIIIa of the blood clotting pathway is stabilized by an interdomain bond between His281 and Ser524 formed in factor VIII.
Wakabayashi H; Monaghan M; Fay PJ
J Biol Chem; 2014 May; 289(20):14020-9. PubMed ID: 24692542
[TBL] [Abstract][Full Text] [Related]
54. Combining mutations that modulate inter-subunit interactions and proteolytic inactivation enhance the stability of factor VIIIa.
Wakabayashi H; Wintermute JM; Fay PJ
Thromb Haemost; 2014 Jul; 112(1):43-52. PubMed ID: 24599523
[TBL] [Abstract][Full Text] [Related]
55. Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.
Wakabayashi H; Fay PJ
J Biol Chem; 2013 Oct; 288(43):31289-97. PubMed ID: 24030831
[TBL] [Abstract][Full Text] [Related]
56. Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.
Bloem E; van den Biggelaar M; Wroblewska A; Voorberg J; Faber JH; Kjalke M; Stennicke HR; Mertens K; Meijer AB
J Biol Chem; 2013 Oct; 288(41):29670-9. PubMed ID: 24009077
[TBL] [Abstract][Full Text] [Related]
57. A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.
Bloem E; Meems H; van den Biggelaar M; Mertens K; Meijer AB
J Biol Chem; 2013 Sep; 288(36):26105-26111. PubMed ID: 23884417
[TBL] [Abstract][Full Text] [Related]
58. Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.
Wakabayashi H; Fay PJ
Biochemistry; 2013 Jun; 52(22):3921-9. PubMed ID: 23659383
[TBL] [Abstract][Full Text] [Related]
59. Domain organization of membrane-bound factor VIII.
Stoilova-McPhie S; Lynch GC; Ludtke S; Pettitt BM
Biopolymers; 2013 Jul; 99(7):448-59. PubMed ID: 23616213
[TBL] [Abstract][Full Text] [Related]
60. Factor VIIIa A2 subunit shows a high affinity interaction with factor IXa: contribution of A2 subunit residues 707-714 to the interaction with factor IXa.
Griffiths AE; Rydkin I; Fay PJ
J Biol Chem; 2013 May; 288(21):15057-64. PubMed ID: 23580639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
